Timothy Lu (@timlu)

Timothy Lu @timlu Dec 11, 2025

Thanks to Dr. Farhad Ravandi from @MDAndersonNews for sharing thoughts on the potential for $SNTI's SENTI-202 product to transform the treatment of AML and other cancers. Published by @VJHemOnc vjhemonc.com/video/nvzwt-du…

www.vjhemonc.com The potential of combining chemotherapy with allogeneic CAR-NK cells in AML: a Phase I trial Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the potential of combining chemotherapy with allogeneic CAR-NK cells in acute myeloid leukemia (AML). Dr...

Timothy Lu @timlu Dec 11, 2025

Thanks to @GeneOnlineNews for highlighting @SentiBio 's recent SENTI-202 data for R/R AML @ ASH. With 50% ORR, RMAT designation, favorable safety, off-the-shelf delivery, we hope to advance this program quickly into pivotal studies for patients in need

geneonline.com/senti-bio-wins…

www.geneonline.com Senti Bio Wins FDA RMAT Designation for SENTI-202 on 50% Response Rate in Leukemia Trial - GeneOn... Senti Biosciences Inc. (Nasdaq: SNTI) recently said that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, the company’s...

Timothy Lu @timlu Dec 10, 2025

$SNTI recently reported our Logic Gated SENTI-202 cell therapy achieved 50% ORR, 42% CR/CRh, 7.6 month cCR durability in heavily pretreated refractory/refractory AML patients at #ASH25. This is an exciting new treatment modality for R/R AML, a disease with a median OS ~5 months

Senti Biosciences Verified account @SentiBio Dec 9, 2025

Dr. Nosha Farhadfar noted that SENTI-202 is demonstrating deep, durable responses and a favorable safety profile in R/R AML, underscoring its potential to selectively target AML cells while preserving healthy ones.

bit.ly/3XFf7ST
$SNTI #AML #ASH2025

View quoted post on X

Timothy Lu @timlu Apr 28, 2025

Excited to share updates on Senti Bio’s SENTI-202 program with Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML. Come join us at 830 AM ET webinar! $SNTI investors.sentibio.com/news-releases/…

investors.sentibio.com Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN... Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D)...

Timothy Lu @timlu Apr 3, 2025

Excited to share the latest clinical and preclinical data on our Logic Gated SENTI-202 product at the upcoming AACR meeting!

Senti Biosciences Verified account @SentiBio Apr 3, 2025

Kanya Rajangam, MD, PhD, President and Chief Medical Officer of $SNTI, shares her excitement for the upcoming data presentation from the SENTI-202 trial at the AACR Annual Meeting being held April 25-30, 2025

bit.ly/3QYtOx5
@AACR

View quoted post on X

Timothy Lu

Latest posts 5